USTRx Act
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in house (Jul 9, 2021)
Use Sovereignty To reduce Rx Act or the USTRx Act
This bill establishes the role of Chief Pharmaceutical Trade Negotiator within the U.S. Trade Representative (USTR) to conduct trade negotiations, enforce trade agreements relating to U.S. pharmaceutical products, and address acts, policies, or practices of high-income countries that adversely impact the market access of U.S. pharmaceutical manufacturers.
The USTR must annually compile a list of high-income countries based on official statistics of the International Bank for Reconstruction and Development of the World Bank. Based on that list, the negotiator must submit a report describing (1) such countries' actions and impacts relating to the pharmaceutical trade, and (2) the current status of any responsive actions taken by the United States.
What just happenedJul 9, 2021
Referred to the Subcommittee on Trade.
Who’s behind it
- Introduced in HouseJul 9, 2021
- Jul 9, 2021Committee
Referred to the Subcommittee on Trade.
Trade Subcommittee - Jul 9, 2021IntroReferralH11100
Referred to the House Committee on Ways and Means.
Ways and Means Committee - Jul 9, 2021IntroReferralIntro-H
Introduced in House
- Jul 9, 2021IntroReferral1000
Introduced in House